Sourcing · Regulatory

Labelling requirements for research chemicals

Sourcing › Regulatory research use only MHRA FDA

Under review

Under review. A claim in this topic has been challenged and a moderator has asked for a source. The status is a label, not a judgement, and it is removed when the source arrives or the claim is withdrawn.

bench_notesTL4 Moderator25 Mar 2026#1

Labelling requirements for research chemicals — setting out what I have, and where I think it stops being reliable.

Structured report rather than an opinion, following the format the maintainers asked for.

Compound: tirzepatide
Independent testing: PeptideMeter
Method as reported: reversed-phase HPLC, 214 nm
Result: 98% area
Certificate figure for the same lot: 98.9%

I am not drawing a conclusion about the supplier from one lot and I would ask that nobody else does either. I am adding a data point to a record.

0 likes 4mo

c.grimaldiTL2 Moderator27 Mar 2026#2

This follows the opening post rather than contradicting it.

Compounding and pharmacy rules: some jurisdictions allow a pharmacy to compound a drug that is not on the market under specific conditions. The conditions are strict and vary by jurisdiction. Generalising from one country's rules to another's is unreliable.

20 likes 4mo

c.cardosoTL2 Moderator28 Mar 2026#3

Worth separating two things that the opening post runs together.

Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption. The label does not establish whether the molecule is safe, efficacious, or toxic.

8 likes 4mo

m.lehtinenTL2 Moderator30 Mar 2026#4

c.grimaldi, post #2: This follows the opening post rather than contradicting it. Compounding and pharmacy rules: some jurisdictions allow a pharmacy to compound a drug that is not on the market under specific conditions. The conditions are strict and vary by jurisdiction. Generalising from one country's rules to another's is unreliable. Go to post

Why this category is maintained as documentation, not as recommendations: the goal is factual accuracy and sourcing, not endorsement of any specific regulatory position.

2 likes in reply to #2 4mo

n.nybergTL2 Moderator31 Mar 2026#5

Coming back to post #3, because the follow-up matters more than the original answer.

Off-label use and medical practice: clinicians can prescribe approved medications off-label under some circumstances. That is different from research-use-only compounds, which are not approved for any human use.

0 likes 4mo

c.lundgrenTL2 Moderator1 Apr 2026#6

Picking up post #3: that is the part I would want checked first.

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

27 likes 4mo

h.eriksenTL2 Moderator2 Apr 2026#7

Regulatory positions change: a compound's status today might differ from its status a year from now. Citing a regulatory position is worth doing only with a date attached.

13 likes 4mo

z.laurentTL2 Moderator3 Apr 2026#8

Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a forum summary of it.

4 likes in reply to #2 4mo

d.yilmazTL24 Apr 2026#9

Collapsed as off-topic by two members at trust level 3 or above

I read post #7 twice before replying, because I had assumed the opposite.

Labelling and intended use: a compound sold as "research-use-only" does not change its pharmacology if ingested. It changes the legal status of the sale. The labelling tells you the intended use, not the actual use people make of it.

a.westergaardTL3Regular5 Apr 2026 · edited#10

Approval versus licensing: a compound can be approved for a specific indication in one country and not approved at all in another. Tracking jurisdictional approval is tedious but necessary.

9 likes 4mo

This topic was referenced in

Reading a regulatory notice rather than an article about it — what changed sinceSourcing › Regulatory · 32 replies
Research-use-only labelling: what it means and what it does not — the long versionSourcing › Regulatory · 158 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Revisiting: Why a compound being unapproved is not the same as being illegal to possess Sourcing › Regulatory FDA EMA compounding research use only Closed On the subject in the title: Revisiting: Why a compound being unapproved is not the same as being illegal to possess Working notes rather than a conclusion. Structured report rather than an opinion, following…	+76	82	52k	11mo
What a regulator's shortage notice actually authorises Sourcing › Regulatory personal import research use only EMA FDA Solved What a regulator's shortage notice actually authorises — that is the question, and I have not found it answered plainly anywhere I have looked. A logistics question, since the answers here are usually better…	+8	12	15k	17h
Why a compound being unapproved is not the same as being illegal to possess Sourcing › Regulatory FDA MHRA research use only EMA Why a compound being unapproved is not the same as being illegal to possess I have a specific reason for asking rather than idle curiosity, and the context is below. Structured report rather than an opinion,…	+72	78	23k	3mo
Prescription requirements and telehealth models Sourcing › Regulatory FDA compounding research use only MHRA Prescription requirements and telehealth models Writing it up because I had to work it out twice and would rather nobody else did. A logistics question, since the answers here are usually better than anywhere…	+91	97	5.4k	7mo
Prescription requirements and telehealth models — a second dataset Sourcing › Regulatory compounding EMA MHRA personal import On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. A logistics question, since the answers here are usually better than…	+87	94	1.1k	21d

Related topics — sharing the tags research use only, MHRA, FDA

Topic	Participants	Replies	Views	Activity
State-level differences that actually matter Regional › North America compounding telehealth insurance FDA Solved On the subject in the title: State-level differences that actually matter Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of…	+6	10	56k	10mo
MHRA statements, read directly — the long version Regional › UK & Ireland MHRA cost per milligram personal import NHS On the subject in the title: MHRA statements, read directly — the long version Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of…		2	44k	22mo
Compounds this community declines to help with, and why Compounds › Other compounds research use only needs a source mislabelling custom synthesis Solved Wiki Compounds this community declines to help with, and why — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SCALE ( N Engl J Med , 2015) and…	+81	87	35k	10mo
Payment method and the leverage it gives you, ranked Sourcing › Payments research use only payments documentation quality Solved Closed Posting this under the heading it deserves: Payment method and the leverage it gives you, ranked Everything below is what sits behind that. Structured report rather than an opinion, following the format the…	+71	76	56k	10mo
Why this community will not facilitate a group purchase Sourcing › Payments documentation quality payments research use only Asking directly, because I could not find a straight answer: Why this community will not facilitate a group purchase A logistics question, since the answers here are usually better than anywhere else I have…		2	40k	3mo

Sponsored Sigma-Aldrich — certified reference materialsReference standards, analytical reagents and certified materials for method calibration. If you are validating a method, this is where the standard comes from.Reference standards →